Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
JCO Precision Oncology|October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyApostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
Scientific Reports|May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiencesShuyang Yao, Funda Meric-Bernstam, David Hong, et al.
JCO Oncology Practice|June 18, 2026
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO GuidelineChristina M Lockwood, Hans J Messersmith, Annette S Kim, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 7, 2017
Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20Björn Konukiewitz, Anna Melissa Schlitter, Moritz Jesinghaus, et al.
Scientific Reports|February 2, 2017
Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypesAnna Melissa Schlitter, Angela Segler, Katja Steiger, et al.
NPJ Precision Oncology|March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) studyApostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
NPJ Precision Oncology|April 29, 2021
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survivalVladimir Lazar, Shai Magidi, Nicolas Girard, et al.
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.
Scientific Reports|August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical TrialTito R Mendoza, David S Hong, Christine B Peterson, et al.
Pageof 11